Sinovac Biotech Ltd (SVA) stock
Close on Nov 12, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech Ltd grew revenue 6.8% to $386.01M over fiscal 2025. Free cash flow was -$561.10M. At the latest close the market valued the company at $464.94M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- $464.94M
- P/E ratio
- –
- Price to sales
- 1.20
- Price to book
- 0.10
- Dividend yield
- 850.08%
- Free cash flow yield
- -120.68%
Fundamentals
- Revenue
- $386.01M
- EPS, diluted
- -$0.83
- Free cash flow
- -$561.10M
Trading
- Previous close
- $6.47
- Open
- $6.47
- Day's range
- $6.47 – $6.47
- Beta (5 years)
- 0.00
- 52-week range
- $6.47 – $6.47
- RSI (14 days)
- 100.0
- Volatility (1 year)
- 0.0%
- WACC
- 7.4%
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | SVA | S&P 500 | Difference | SVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | 0.0% | -2.7% | +2.7 pts | ||
| 3 months | 0.0% | -1.7% | +1.7 pts | ||
| Year to date | 0.0% | +11.9% | −11.9 pts | ||
| 1 year | 0.0% | +12.0% | −12.0 pts | ||
| 3 years | 0.0% | +78.2% | −78.2 pts | 0.0% | +21.2% |
| 5 years | 0.0% | +73.2% | −73.2 pts | 0.0% | +11.6% |
| 10 years | +4.9% | +309.6% | −304.8 pts | +0.5% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Sinovac Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Sinovac Biotech
Pharmaceutical Preparations
Sinovac Biotech Ltd. is a biopharmaceutical company engaged in researching, developing, manufacturing, and commercializing human vaccines against infectious diseases. Its commercial product portfolio includes vaccines for hepatitis A, hepatitis B, enterovirus 71 hand-foot-and-mouth disease, seasonal influenza, poliomyelitis, pneumococcal disease, varicella, and tetanus. The company's customer base encompasses domestic private-pay consumers and public immunization programs in China, sovereign health systems, and international procurement organizations such as United Nations agencies.
Company profile, executives and historySinovac Biotech stock: common questions
What is Sinovac Biotech's stock price?
SVA closed at $6.47 on Nov 12, 2026, up 0.00% on the day. Over the past 52 weeks it traded between $6.47 and $6.47.
What is Sinovac Biotech's market cap?
Sinovac Biotech was worth $464.94M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is SVA's P/E ratio?
Sinovac Biotech lost money over fiscal 2025 (diluted EPS -$0.83), so it has no meaningful P/E ratio.
How much revenue does Sinovac Biotech make?
Sinovac Biotech reported revenue of $386.01M for fiscal 2025, up 6.8% from a year earlier.
Does Sinovac Biotech pay a dividend?
Yes. Sinovac Biotech paid $55.00 per share over the last twelve months, a yield of 850.08% at the latest price.
How has SVA stock performed over the past year?
Including dividends, SVA returned 0.0% over the past year, against +12.0% for the S&P 500.
How many SVA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.33% of the float, or 1000.0 days of average trading volume.
Who are Sinovac Biotech's competitors?
Companies most similar to Sinovac Biotech by business, industry and size include HCM, ZLAB, AAPG, NVAX, KMDA.
See a number that looks wrong?